Santersus completes first clinical trial for sepsis and Covid-19 treatment

Deucrictibant IR NDA under review by the FDA with PDUFA date of April 23, 2027 Topline data from part 1 of CREAATE, a pivotal Phase 3 study evaluating deucrictibant XR for the prophylaxis of AAE-C1INH attacks, expected in 1Q2027; enrollment ongoing in part 2 of CREAATE evaluating deucrictibant IR for the on-demand treatment of AAE-C1INH attacks Preparation of NDA dossier of deucrictibant XR for pr

abc biopply AG, Europe's fully integrated Organoid CRO, and Panome Bio, a leading US multi-omics CRO specializing in Next-Generation Metabolomics and integrated multi-omics analysis, today announced the signing of a strategic collaboration agreement aimed at expanding the availability of standardized, human-relevant preclinical data generation and advanced molecular analytics for pharmaceutical an

Peer-Reviewed Publication in Clinical & Experimental Allergy Reveals Potential Disease-Modifying Effect of Mabylon’s Allergen-Neutralizing Antibodies Allergen-specific, human-derived IgG4 antibodies prevent allergic reactions by neutralizing allergens and redirecting them toward tolerance-associated immune pathways. Mechanism-of-action observed across different allergy indications. Study pro

Preclinical program will evaluate Topadur’s locally acting compounds, including clinical-stage TOP-N53, in dystrophic epidermolysis bullosa Studies in collaboration with the Medical Center – University of Freiburg and the EB Research Institute in Salzburg

Oversubscribed €120 million Series D financing was led by M Ventures and Revelation Partners, with new investors Angelini Industries, the European Investment Bank and Neva SGR and participation from all existing investors. Proceeds will fund advancement of Nouscom’s lead asset NOUS-209, an investigational, off-the-shelf neoantigen-based cancer immunotherapy, through a global, registration-enab